PRATH
Preclinical study of Recombinant human Anti-C5 for the Treatment of atypical HUS
| Coordinatore | ADIENNE S.r.l.
Organization address
address: Via Broseta 64/B contact info |
| Nazionalità Coordinatore | Italy [IT] |
| Sito del progetto | http://www.prath.eu/ |
| Totale costo | 2˙528˙472 € |
| EC contributo | 1˙804˙435 € |
| Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
| Code Call | FP7-HEALTH-2009-single-stage |
| Funding Scheme | CP-FP |
| Anno di inizio | 2010 |
| Periodo (anno-mese-giorno) | 2010-05-01 - 2012-04-30 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
ADIENNE S.r.l.
Organization address
address: Via Broseta 64/B contact info |
IT (Bergamo) | coordinator | 975˙372.00 |
| 2 |
CIT SAS
Organization address
address: MISEREY contact info |
FR (EVREUX) | participant | 387˙000.00 |
| 3 |
IMPERIAL COLLEGE OF SCIENCE, TECHNOLOGY AND MEDICINE
Organization address
address: SOUTH KENSINGTON CAMPUS EXHIBITION ROAD contact info |
UK (LONDON) | participant | 235˙663.00 |
| 4 |
UNIVERSITA DEGLI STUDI DI TRIESTE
Organization address
address: PIAZZALE EUROPA 1 contact info |
IT (TRIESTE) | participant | 206˙400.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'The Complement System is implicated in the onset, maintenance and amplification of tissue damage in several inflammatory clinical conditions. Haemolytic uraemic syndrome (HUS) is a systemic disease characterized by damage to endothelial cells and erythrocytes, thrombocytopenia, micro thrombosis and kidney failure. During the last few years it has become evident that familial atypical HUS is strongly associated with mutations in proteins needed either for activation or regulation of the alternative pathway of Complement. For this reason, ADIENNE S.r.l. (Italy) has obtained orphan designation EU/3/08/571 for its Recombinant human minibody against Complement component C5 for the treatment of atypical Haemolytic Uraemic Syndrome (aHUS) associated with an inherited abnormality of the Complement system in September 2008. This molecule has been already characterized by in vitro and in vivo experiments and a complete preclinical study is the next step for the development of this potential orphan drug useful for the treatment of aHUS. Preclinical studies of this EU designated orphan medicinal product has been design by ADIENNE S.r.l. and will be perform in collaboration with the University of Trieste (which has isolated and characterized the recombinant human antibody against C5), the Imperial Collage of London, ADIENNE Spain SL and CIT-Safety and Health Research Laboratories. In this two years project we plan to perform pharmacological, pharmacokinetic and toxicological studies, a pre-clinical evaluation of the therapeutic efficacy of the anti-C5 antibody in mouse models of aHUS and characterization of GMP-grade anti-C5 antibody production. Data collected in this project will be sufficient for a complete “Preclinical development of substances with a clear potential as orphan drugs” as proposed in topic “Rare diseases - HEALTH-2009-2.4.4-2”.'
Introduzione (Teaser)
During pathogen invasion our body recruits immune cells and antibodies to fight the infection, a response that is also aided by a collection of proteins known as the complement system. Excessive activation of the Complement System leads to disease and pharmaceutical efforts to prevent this are urgently required.